We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. (Incorporated in Australia)

A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — for pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent pending multiple-ingredient dosage forms, and that we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (“white label”). 

**Note: Revenue and net loss figures are in U.S. dollars (converted from Australian dollars) for the year that ended June 30, 2022.

(Note: Gelteq Ltd. filed an F-1/A dated Dec. 9, 2022, in which it disclosed updated financial statements for the year ended June 30, 2022. Gelteq Ltd. filed its F-1 dated Aug. 30, 2022,  in which it disclosed terms: 1.3 million shares at $5.00 to raise $6.5 million. The company filed confidential IPO documents on March 31, 2022.)